CEST vs. DWI: Capability for Distinguishing Malignant from Benign Prostatic Areas in Patients with Prostatic Cancer
Takahiro Ueda1, Yoshiharu Ohno1,2, Kaori Yamamoto3, Masao Yui3, Masato Ikedo3, Saki Takeda4, Akiyoshi Iwase4, Yuka Oshima1, Nayu Hamabuchi1, Satomu Hanamatsu1, Yuki Obama1, Hiroyuki Nagata1, Hirotaka Ikeda1, Kazuhiro Murayama2, and Hiroshi Toyama1
1Radiology, Fujita Health University School of Medicine, Toyoake, Japan, 2Joint Research Laboratory of Advanced Medical Imaging, Fujita Health University School of Medicine, Toyoake, Japan, 3Canon Medical Systems Corporation, Otawara, Japan, 4Radiology, Fujita Health University Hospital, Toyoake, Japan
We hypothesize that CEST is at least as valuable as DWI and may have a potential to improve differentiation capability of malignant from benign prostatic areas as one of the combined quantitative discriminators on prostatic MR imaging. The purpose of this study was to compare the capability for distinguishing malignant from benign areas among CEST, DWIs at standard and super high b values and combined quantitative discriminator in suspected prostatic cancer patients.
This abstract and the presentation materials are available to members only;
a login is required.